Showing 15,421 - 15,440 results of 46,968 for search '(( 50 ((a decrease) OR (nn decrease)) ) OR ( 5 ((mm decrease) OR (mean decrease)) ))', query time: 0.80s Refine Results
  1. 15421
  2. 15422

    Dual Inhibition of Topoisomerase II and Tyrosine Kinases by the Novel Bis-Fluoroquinolone Chalcone-Like Derivative HMNE3 in Human Pancreatic Cancer Cells by Yong-Chao Ma (174419)

    Published 2016
    “…Consistent with cellular apoptosis data, a significant decrease in topoisomerase IIβ activity was noted following treatment with HMNE3 for 24 h. …”
  3. 15423

    DRP2B is partially required for flg22-induced endocytosis of FLS2. by John M. Smith (676719)

    Published 2014
    “…Representative maximum-intensity projection images and zoomed insets of FLS2-GFP fluorescence are shown, with bright pixels corresponding to increased abundance of FLS2-GFP at a given location. Scale bars = 10 µm. (D) Quantification of FLS2-GFP in puncta at 0, 35–45 or 50–60 min after elicitation with 1 µM flg22 indicates that loss of <i>DRP2B</i> resulted in ∼20% decrease in flg22-stimulated endocytosis of FLS2-GFP (35–45 min, P = 0.0204; 50–60 min, P = 0.0396). …”
  4. 15424

    Vascular nitrite concentrations at rest and following ischemia in control and diabetic subjects. by Ashley P. Pettit (836968)

    Published 2015
    “…<p>Blood draws were taken at rest and 60sec following release (hyperemia) of the five minute upper arm occlusion (50mmHg above SBP) before and following the ride. …”
  5. 15425
  6. 15426
  7. 15427
  8. 15428
  9. 15429
  10. 15430
  11. 15431

    Mcl-1 degradation is slowed by a T163E mutation (but not T163A) in transfected CHO cells. by Shanna K. Nifoussi (128297)

    Published 2012
    “…In Panel B, the decline in Mcl-1 expression at 3 hours in 2 independent experiments ranged from 53–66% with WT-Mcl-1, 25–54% with Mcl-1-S162A, and 25–50% with Mcl-1-T163A. While the decline in expression with WT-Mcl-1 appeared be slightly greater than that seen with Mcl-1-T163A, this was not a consistent finding. …”
  12. 15432
  13. 15433
  14. 15434

    Baseline characteristics. by Si-Jing Chen (15350263)

    Published 2025
    “…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
  15. 15435

    Secondary outcome results. by Si-Jing Chen (15350263)

    Published 2025
    “…In addition, the CBT-I group reported a greater decrease in depressive (adjusted difference −1.0 [−1.6 to −0.5]; Cohen’s <i>d</i> = 0.53; <i>p</i> < 0.001) and insomnia symptoms (−2.0 [−2.7 to −1.3], <i>d</i> = 0.78; <i>p</i> < 0.001) than the controls at post-intervention and throughout 6-month follow-up. …”
  16. 15436
  17. 15437
  18. 15438
  19. 15439
  20. 15440